Impact Partnership Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Impact Partnership Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$294K	Buy	592 +131	+28%	+$58.1K	0.03%	350
2026 Q1	$206K	Sell	461 -19	-4%	-$8.86K	0.03%	341
2025 Q4	$218K	Buy	+480	New	+$207K	0.03%	330
2024 Q2	–	Sell	-828	Closed	-$346K	–	675
2024 Q1	$346K	Buy	828 +16	+2%	+$6.76K	0.14%	109
2023 Q4	$330K	Sell	812 -197	-20%	-$72.8K	0.12%	111
2023 Q3	$351K	Buy	+1,009	New	+$353K	0.11%	107

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Impact Partnership Wealth's VRTX Position: Q2 2026 in Review

Impact Partnership Wealth increased its Vertex Pharmaceuticals (VRTX) stake by 28% in Q2 2026, buying an estimated $58.1K and bringing the position to 592 shares worth $294K. The position accounts for 0.03% of the portfolio, ranked #350.

Impact Partnership Wealth first reported a position in VRTX in Q3 2023 and has held it in 6 quarters since. The position peaked at $351K in Q3 2023. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Impact Partnership Wealth held 592 shares of Vertex Pharmaceuticals worth $294K as of Q2 2026.
Impact Partnership Wealth bought 131 Vertex Pharmaceuticals shares in Q2 2026, an estimated $58.1K.
Vertex Pharmaceuticals made up 0.03% of Impact Partnership Wealth's portfolio in Q2 2026, its #350 holding.
Impact Partnership Wealth first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 6 quarters since.
Impact Partnership Wealth's Vertex Pharmaceuticals position peaked at $351K in Q3 2023.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Impact Partnership Wealth's 13F filing for Q2 2026, filed 29 Jul 2026.